Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Slides:

Advertisements

Similar presentations

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Advertisements

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Uncontrolled Wnt signaling causes leukemia

Do HSCs divide asymmetrically?

MBL: mostly benign lymphocytes, but…

Collaboration is required for successful immunotherapy

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

Next-generation leukemia immunotherapy

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Gupta V, Tallman MS, Weisdorf DJ

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Tax fingerprint in adult T-cell leukemia

A cell by any other name by Narla Mohandas Blood

Mechanisms of HIV-associated lymphocyte apoptosis

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma by Chan Yoon Cheah, Loretta J. Nastoupil,

T regulatory cells turn on T regulatory cells

CMV: when bad viruses turn good

Acute promyelocytic leukemia, microgranular variant

Suppression, surprise: galectin-10 and Treg cells

Taking a leaf from the book of oral tolerance

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Stage C or not stage C…? by Claire Dearden Blood

Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Chronic Myeloid Leukemia

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Activity of eltrombopag in severe aplastic anemia

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

by Seth J. Rotz, Nathan Luebbering, Bradley P

by Alex Aleshin, and Peter L. Greenberg

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

by Geling Li, Emily Waite, and Julie Wolfson

BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia by Karen A. Dun, Rob Vanhaeften, Tracey J.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Saad S. Kenderian, David L. Porter,

Volume 2(Supplement 1):1-3

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia by Thai Hoa Tran, Marian.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

by Christine L. Kempton, and Amanda B. Payne

Volume 2(Supplement 1):46-49

by Michael R. DeBaun, and Ellen Wright Clayton

Ontogeny of platelet function

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking by Juliet N. Barker, Jane Kempenich, Joanne.

Resistance mechanism for ibrutinib in marginal zone lymphoma

Anti-CD20-IL-21 fusokine: the tail wags the dog

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

Rituximab immunotherapy: it’s getting personal

by Deogratias Ruhangaza, Andrew G. Evans, and Elizabeth A. Morgan

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Volume 2(Supplement 1):4-7

Presentation transcript:

Immunotherapy for acute lymphoblastic leukemia: from famine to feast by Kara L. Davis, and Crystal L. Mackall BloodAdv Volume 1(3):265-269 December 27, 2016 © 2016 by The American Society of Hematology

Overview of administration and kinetics of CAR T cells. Overview of administration and kinetics of CAR T cells. (A) Overview of CAR T-cell manufacturing and administration. (B) Impact of CAR T-cell costimulatory domain (CD28 or 4-1BB) on kinetics and duration of CAR T cells. Kara L. Davis, and Crystal L. Mackall Blood Adv 2016;1:265-269 © 2016 by The American Society of Hematology